查看购物车
  • Traditional Chinese
  • English
2021-2031年亚太临床试验市场报告：范围、细分、动态和竞争分析
市场调查报告书
商品编码
1871412

2021-2031年亚太临床试验市场报告：范围、细分、动态和竞争分析

Asia Pacific Clinical Trials Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 129 Pages | 订单完成后即时交付

价格

预计亚太地区临床试验市场将显着成长，到 2031 年将达到约 167.6221 亿美元，高于 2023 年的 93.3952 亿美元，在此期间的年复合成长率(CAGR) 为 7.6%。

执行摘要和市场分析

亚太地区被公认为临床试验成长最快的市场，涵盖中国、日本、印度、韩国、澳洲、印尼、新加坡、马来西亚等国家。值得注意的是，澳洲、印度和韩国等国家由于医疗保健产业的进步，蓄势待发，可望快速成长。这些国家的政府积极推动临床试验，加上慢性病盛行率不断上升以及公众对临床试验的认知度不断提高，预计将在不久的将来为市场参与者创造巨大的机会。

市场区隔分析

亚太地区临床试验市场可依研究设计、适应症及阶段类型进行细分：

  • 研究设计：市场分为干预性试验和扩大准入试验，到 2023 年，干预性试验将占据市场份额的主导地位。
  • 适应症：主要领域包括自体免疫/发炎、疼痛管理、肿瘤、神经系统疾病、糖尿病、肥胖、代谢性疾病、心血管疾病等。 2023年，肿瘤领域占据主导地位。
  • 阶段类型：市场分为 I 期、II 期和 III 期试验，其中 II 期在 2023 年占据最大的市场份额。

市场展望

研究在製药、生物製药和医疗器材产业中发挥着至关重要的作用，它促进了具有巨大医疗和商业潜力的新型治疗方案的开发。製药业是全球研发投入最高的产业之一，致力于提高疗效和效率，以满足患者的需求。药品成本的不断上涨促使製药公司加大研发投入，以实现成本目标。过去十年，新药的年度获批率持续成长，研发支出对于发现、测试和生产新产品以及确保符合监管要求至关重要。

根据美国药品研究与製造商协会（PhRMA）成员公司2021年发布的报告，前15位的製药公司在研发方面共投入1,330亿美元，其中约44%用于临床试验。这些公司与医院的合作正在推动包括免疫系统疾病在内的多种疾病疗法的研发。例如，武田製药于2021年6月启动了ADVANCE-1试验，旨在评估HYQVIA治疗慢性发炎性脱髓鞘性多发性神经根神经病变（CIDP）的疗效。

国家概况

亚太临床试验市场涵盖中国、日本、印度、澳洲、韩国、印尼、马来西亚、新加坡等主要国家。 2023年，中国凭藉其成熟的製药产业、不断增长的研发投入、成本降低带来的临床试验数量激增以及完善的监管框架，成为亚太地区最大的市场。作为全球第二大医药市场，中国庞大的人口基数以及传染病和非传染性疾病发病率的不断上升，正推动其医药产业的蓬勃发展，使其成为开展临床试验的理想之地。

中国对药物临床试验的大力支持加速了新药研发过程。 《中国新药临床试验进展年度报告》显示，註册临床试验数量稳定成长，从2021年的3,358项增加至2023年的4,300项。此外，500种生物製品获批上市，其中肿瘤、皮肤病和内分泌是重要的治疗领域。中国也成为国际製药公司寻求缩短产品研发週期和降低研发成本的理想研发外包目的地。西方公司参与中国临床试验的数量也从2010年的每年约100项增加至2021年的约350项。

近年来，中国医药产业专注于研发创新药物。例如，2021年，纽安斯製药与维罗纳製药合作，在大中华区开发恩西芬特林，并于2023年4月启动了该药物作为慢性阻塞性肺病维持治疗的III期临床试验。

公司简介

临床试验市场的主要参与者包括QVIA Holdings Inc、Parexel International Corp、IXICO Plc、Charles River Laboratories、ICON Plc、药明康德、SGS SA、Syneos Health、Thermo Fisher Scientific、Laboratory Corp of America、CliniRx Research、Caidya、Oracle CorpRO、Medpace和SI Clinpharm。这些公司正透过扩张、产品创新以及併购等多种策略来增强市场份额并提供创新解决方案。

目录

第一章：引言

第二章：执行概要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基础数字：
    • 数据三角测量：
    • 国家层面资料：
  • 假设和局限性

第四章：亚太地区临床试验市场概况

  • 概述
  • PEST分析
  • 生态系分析
  • 价值链中的供应商列表

第五章：亚太临床试验市场－主要市场动态

  • 亚太临床试验市场—主要市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来趋势

驾驶员和安全带的影响：

第六章：亚太临床试验市场分析

  • 2021-2031年亚太临床试验市场收入
  • 亚太临床试验市场预测分析

第七章：亚太地区临床试验市场分析－依研究设计划分

  • 干预性试验
  • 扩大使用试验

第八章：亚太地区临床试验市场分析－依适应症划分

  • 自体免疫/炎症
  • 疼痛管理
  • 肿瘤学
  • 神经系统疾病
  • 糖尿病
  • 肥胖
  • 代谢紊乱
  • 心血管
  • 其他的

第九章：亚太地区临床试验市场分析－依阶段类型划分

  • 第一阶段
  • 第二阶段
  • 第三阶段

第十章：亚太临床试验市场—国家分析

  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 印尼
    • 马来西亚
    • 新加坡
    • 亚太其他地区

第十一章：竞争格局

  • 关键参与者热力图分析
  • 公司定位与集中度

第十二章：行业概况

  • 概述
  • 市场拓展计划
  • 伙伴关係与合作
  • 其他进展

第十三章：公司简介

  • IQVIA Holdings Inc
  • Parexel International Corp
  • IXICO Plc
  • Charles River Laboratories International Inc
  • ICON Plc
  • WuXi AppTec Co Ltd
  • SGS SA
  • Syneos Health Inc
  • SIRO Clinpharm Pvt Ltd
  • Thermo Fisher Scientific Inc
  • Laboratory Corp of America Holdings
  • CliniRx Research Private Limited
  • Caidya
  • Oracle Corp
  • Medpace Holdings Inc

第十四章：附录

Product Code: BMIRE00028988

The Asia Pacific clinical trials market is projected to grow significantly, reaching approximately US$ 16,762.21 million by 2031, up from US$ 9,339.52 million in 2023, reflecting a compound annual growth rate (CAGR) of 7.6% during this period.

Executive Summary and Market Analysis

The Asia Pacific (APAC) region is recognized as the fastest-growing market for clinical trials, encompassing countries such as China, Japan, India, South Korea, Australia, Indonesia, Singapore, Malaysia, and others. Notably, nations like Australia, India, and South Korea are poised for growth due to advancements in their healthcare sectors. Governments in these countries are actively promoting clinical trials, which, combined with the rising prevalence of chronic diseases and increased awareness of clinical trials, is expected to create substantial opportunities for market participants in the near future.

Market Segmentation Analysis

The Asia Pacific clinical trials market can be segmented based on study design, indications, and phase type:

  • Study Design: The market is divided into interventional trials and expanded access trials, with interventional trials dominating the market share in 2023.
  • Indications: Key segments include autoimmune/inflammation, pain management, oncology, neurological disorders, diabetes, obesity, metabolic disorders, cardiovascular diseases, and others. Oncology was the leading segment in 2023.
  • Phase Type: The market is categorized into phase I, phase II, and phase III trials, with phase II holding the largest market share in 2023.

Market Outlook

Research plays a crucial role in the pharmaceutical, biopharmaceutical, and medical device industries, facilitating the development of new therapeutic solutions with significant medical and commercial potential. The pharmaceutical sector is among the most research and development (R&D)-intensive industries globally, striving for enhanced effectiveness and efficiency in meeting patient needs. The rising costs of medications have prompted pharmaceutical companies to invest heavily in R&D to achieve their cost targets. Over the past decade, the annual approval rate of new drugs has increased, with R&D expenditures being vital for discovering, testing, and producing new products, as well as ensuring regulatory compliance.

According to a 2021 report by PhRMA Member Companies, the top 15 pharmaceutical companies collectively invested US$ 133 billion in R&D, with approximately 44% allocated to clinical trials. Collaborations between these companies and hospitals are driving the development of treatments for various diseases, including immunological disorders. For instance, in June 2021, Takeda initiated the ADVANCE-1 trial to evaluate HYQVIA for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Country Insights

The Asia Pacific clinical trials market includes key countries such as China, Japan, India, Australia, South Korea, Indonesia, Malaysia, Singapore, and others. China emerged as the largest market in 2023, driven by its established pharmaceutical sector, increased R&D spending, a growing number of clinical trials due to lower costs, and supportive regulatory frameworks. With the world's second-largest pharmaceutical market, China's vast population and rising incidence of both communicable and non-communicable diseases are propelling the growth of its pharmaceutical industry, making it a prime location for clinical trials.

China's commitment to supporting drug clinical trials has accelerated new drug development. The Annual Report on the Progress of Clinical Trials for New Drug Registration in China indicates a steady increase in registered clinical trials, from 3,358 in 2021 to 4,300 in 2023. Additionally, 500 biological products were approved, with oncology, dermatology, and endocrinology being significant therapeutic areas. The country has also become an attractive R&D outsourcing destination for international pharmaceutical firms seeking to reduce product timelines and costs. The involvement of Western companies in clinical trials in China has risen from about 100 trials per year in 2010 to approximately 350 in 2021.

In recent years, the Chinese pharmaceutical industry has focused on R&D to innovate new drugs. For example, in 2021, Nuance Pharma entered a partnership with Verona Pharma for the development of ensifentrine in Greater China, and in April 2023, they initiated a Phase III trial for this drug as a maintenance treatment for chronic obstructive pulmonary disease.

Company Profiles

Key players in the clinical trials market include QVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories, ICON Plc, WuXi AppTec, SGS SA, Syneos Health, Thermo Fisher Scientific, Laboratory Corp of America, CliniRx Research, Caidya, Oracle Corp, Medpace, and SIRO Clinpharm. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:
  • 3.3 Assumptions and Limitations

4. Asia Pacific Clinical Trials Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
  • 4.4 List of Vendors in the Value Chain

5. Asia Pacific Clinical Trials Market - Key Market Dynamics

  • 5.1 Asia Pacific Clinical Trials Market - Key Market Dynamics
  • 5.2 Market Drivers
  • 5.3 Market Restraints
  • 5.4 Market Opportunities
  • 5.5 Future Trends

Impact of Drivers and Restraints:

6. Asia Pacific Clinical Trials Market - Analysis

  • 6.1 Asia Pacific Clinical Trials Market Revenue (US$ Million), 2021-2031
  • 6.2 Asia Pacific Clinical Trials Market Forecast Analysis

7. Asia Pacific Clinical Trials Market Analysis - by Study Design

  • 7.1 Interventional Trials
    • 7.1.1 Overview
    • 7.1.2 Interventional Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Expanded Access Trials
    • 7.2.1 Overview
    • 7.2.2 Expanded Access Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Clinical Trials Market Analysis - by Indications

  • 8.1 Autoimmune/Inflammation
    • 8.1.1 Overview
    • 8.1.2 Autoimmune/Inflammation: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Pain Management
    • 8.2.1 Overview
    • 8.2.2 Pain Management: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Neurological Disorders
    • 8.4.1 Overview
    • 8.4.2 Neurological Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.5 Diabetes
    • 8.5.1 Overview
    • 8.5.2 Diabetes: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.6 Obesity
    • 8.6.1 Overview
    • 8.6.2 Obesity: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.7 Metabolic Disorders
    • 8.7.1 Overview
    • 8.7.2 Metabolic Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.8 Cardiovascular
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.9 Others
    • 8.9.1 Overview
    • 8.9.2 Others: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Clinical Trials Market Analysis - by Phase Type

  • 9.1 Phase I
    • 9.1.1 Overview
    • 9.1.2 Phase I: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Phase II
    • 9.2.1 Overview
    • 9.2.2 Phase II: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Phase III
    • 9.3.1 Overview
    • 9.3.2 Phase III: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Clinical Trials Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 China: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.2.2 China: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.2.3 China: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.3 Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 Japan: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.3.2 Japan: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.3.3 Japan: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.4 India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 India: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.4.2 India: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.4.3 India: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.5 Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 Australia: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.5.2 Australia: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.5.3 Australia: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.6 South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 South Korea: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.6.2 South Korea: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.6.3 South Korea: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.7 Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Indonesia: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.7.2 Indonesia: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.7.3 Indonesia: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.8 Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.8.1 Malaysia: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.8.2 Malaysia: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.8.3 Malaysia: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.9 Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.9.1 Singapore: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.9.2 Singapore: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.9.3 Singapore: Asia Pacific Clinical Trials Market Share - by Phase Type
      • 10.1.1.10 Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.10.1 Rest of APAC: Asia Pacific Clinical Trials Market Share - by Study Design
        • 10.1.1.10.2 Rest of APAC: Asia Pacific Clinical Trials Market Share - by Indications
        • 10.1.1.10.3 Rest of APAC: Asia Pacific Clinical Trials Market Share - by Phase Type

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Market Initiative
  • 12.3 Partnerships and Collaborations
  • 12.4 Other Developments

13. Company Profiles

  • 13.1 IQVIA Holdings Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Parexel International Corp
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 IXICO Plc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Charles River Laboratories International Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 ICON Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 WuXi AppTec Co Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 SGS SA
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Syneos Health Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 SIRO Clinpharm Pvt Ltd
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Thermo Fisher Scientific Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Laboratory Corp of America Holdings
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 CliniRx Research Private Limited
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments
  • 13.13 Caidya
    • 13.13.1 Key Facts
    • 13.13.2 Business Description
    • 13.13.3 Products and Services
    • 13.13.4 Financial Overview
    • 13.13.5 SWOT Analysis
    • 13.13.6 Key Developments
  • 13.14 Oracle Corp
    • 13.14.1 Key Facts
    • 13.14.2 Business Description
    • 13.14.3 Products and Services
    • 13.14.4 Financial Overview
    • 13.14.5 SWOT Analysis
    • 13.14.6 Key Developments
  • 13.15 Medpace Holdings Inc
    • 13.15.1 Key Facts
    • 13.15.2 Business Description
    • 13.15.3 Products and Services
    • 13.15.4 Financial Overview
    • 13.15.5 SWOT Analysis
    • 13.15.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 List of Abbreviations

List Of Tables

  • Table 1. Asia Pacific Clinical Trials Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 4. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Study Design
  • Table 5. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 6. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Phase Type
  • Table 7. Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 9. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 10. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 11. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 12. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 13. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 14. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 15. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 16. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 17. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 18. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 19. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 20. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 21. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 22. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 23. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 24. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 25. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 26. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 27. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 28. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 29. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 30. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 31. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 32. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 33. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 34. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 35. List of Abbreviations

List Of Figures

  • Figure 1. Asia Pacific Clinical Trials Market Segmentation - Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Clinical Trials Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Clinical Trials Market Share (%) - by Study Design (2023 and 2031)
  • Figure 6. Interventional Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Expanded Access Trials: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Asia Pacific Clinical Trials Market Share (%) - by Indications (2023 and 2031)
  • Figure 9. Autoimmune/Inflammation: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Pain Management: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Oncology: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Neurological Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Diabetes: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Obesity: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Metabolic Disorders: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Cardiovascular: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Others: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Asia Pacific Clinical Trials Market Share (%) - by Phase Type (2023 and 2031)
  • Figure 19. Phase I: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Phase II: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Phase III: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Asia Pacific Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. China: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. Japan: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. India: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. Australia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. South Korea: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Indonesia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 29. Malaysia: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 30. Singapore: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 31. Rest of APAC: Asia Pacific Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 32. Heat Map Analysis by Key Players
  • Figure 33. Company Positioning and Concentration